Anti-TNF-alpha therapy in ankylosing spondylitis

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Ankylosing spondylitis (AS) causes significant functional impairment and socioeconomic burden.
• Anti-tumor necrosis factor-alpha (TNF-alpha) therapies, including infliximab and etanercept, have emerged as promising treatments for AS.
• Previous open-label studies indicated the feasibility and efficacy of these biologic agents.

Purpose of the Study:

• To review the current evidence on the efficacy and safety of anti-TNF-alpha therapy in treating ankylosing spondylitis.
• To discuss the observed clinical, functional, and imaging improvements associated with anti-TNF-alpha agents.
• To identify remaining questions regarding long-term outcomes, structural benefits, and cost-effectiveness.

Main Methods:

• Review of open-label and controlled studies evaluating infliximab and etanercept in AS patients.
• Analysis of clinical parameters, functional assessments, quality of life measures, and biological markers.
• Inclusion of magnetic resonance imaging (MRI) findings related to inflammation.

Main Results:

• Controlled studies confirm short-term (1-year) efficacy of anti-TNF-alpha therapy in AS.
• Significant improvements observed in clinical parameters, function, quality of life, and MRI-detected inflammation.
• Anti-TNF-alpha therapies are approved for AS treatment, with established guidelines for use.

Conclusions:

• Anti-TNF-alpha therapy represents a major therapeutic advancement for ankylosing spondylitis.
• Key safety concerns primarily involve infection risks.
• Further research is needed on long-term efficacy, safety, structural benefits, and cost-effectiveness.